Contact Us
Drug Search Results
More Filters [+]

JNJ-88998377

Alternative Names: JNJ-88998377, JNJ 88998377, JNJ88998377
Latest Update: 2024-06-28
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: TRPV1 Antagonist

Novel Mechanism: Yes

Modality: N/A

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Johnson & Johnson
Company Location: NEW BRUNSWICK NJ 08933
Company CEO: Joaquin Duato
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for JNJ-88998377

Countries in Clinic: China, Italy, Poland, Turkey, Unknown Location

Active Clinical Trial Count: 2

Highest Development Phases

Phase 1: Lymphoma, B-Cell|Lymphoma, Non-Hodgkin

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
88998377LYM1001

P1

Recruiting

Lymphoma, Non-Hodgkin|Lymphoma, B-Cell

2027-10-29

jRCT2031240200

P1

Not yet recruiting

Lymphoma, B-Cell|Lymphoma, Non-Hodgkin

2027-10-06

Recent News Events

Date

Type

Title

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions